Imagine a future where cancer treatment in the Middle East takes a giant leap forward. That future is now a reality, thanks to a groundbreaking partnership between YAS Healthcare and IBA, the global leader in particle accelerator technology. But here's where it gets exciting: Dubai is set to become home to the Gulf Cooperation Council (GCC) region’s first-ever proton therapy center, a cutting-edge facility that promises to revolutionize cancer care.
In a landmark deal announced on December 8, 2025, YAS Healthcare, a subsidiary of DAS Holding, signed a contract with IBA to install the Proteus®ONE proton therapy system in Dubai, United Arab Emirates (UAE). This compact, state-of-the-art solution is not just a technological marvel; it’s a beacon of hope for patients seeking advanced cancer treatment options.
And this is the part most people miss: Proton therapy is considered the most advanced form of radiation therapy available today, offering precision targeting of tumors while minimizing damage to surrounding healthy tissue. With the Proteus®ONE system, YAS Healthcare is poised to deliver this life-changing treatment to patients starting in 2029.
The contract includes the supply of the latest generation of proton therapy technology, along with a multi-year operation and maintenance agreement. What sets Proteus®ONE apart is its upgradability, ensuring that patients always have access to the most advanced treatment options. The system’s typical end-user price, including maintenance, ranges between €35 and €45 million—a significant investment in the future of healthcare.
Olivier Legrain, CEO of IBA, expressed his pride in the partnership: “We are honored to collaborate with YAS Healthcare and bring proton therapy to this region, where it will undoubtedly benefit countless patients. This contract underscores IBA’s commitment to technological innovation and our leadership in the field.”
Dr. Mohammed Zaki, Medical Director & General Manager of YAS Healthcare, added: “After a meticulous selection process, we chose IBA for their unparalleled expertise in proton therapy technology. This achievement comes just five months after securing preliminary approval from the Dubai Health Authority (DHA) to build the UAE’s first proton therapy center. We are thrilled to be at the forefront of advancing cancer treatment in the region.”
But here’s the controversial question: As proton therapy becomes more accessible, will it remain an elite treatment, or can we expect it to become a standard option for cancer patients worldwide? Let’s discuss in the comments.
For IBA, this partnership reinforces their position as the world leader in particle accelerator technology, with a global workforce of approximately 2,100 employees. As a certified B Corporation, IBA is committed to meeting the highest standards of social and environmental performance.
YAS Healthcare, established in 2014, has built a reputation as a leading healthcare provider in Abu Dhabi, guided by its mission to deliver high-quality medical services with a focus on ethics and patient care. Their vision to meet the evolving medical needs of patients aligns perfectly with this groundbreaking initiative.
As we celebrate this milestone, one thing is clear: the future of cancer treatment in the UAE and beyond is brighter than ever. What are your thoughts on this development? Do you think proton therapy will become more widely available, or will it remain a specialized treatment? Share your opinions below!
